Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease

BASS, JAMES W., FREITAS, BONNIE CARY, FREITAS, ALEXANDER D., SISLER, CHERYL L., CHAN, DEBORA S., VINCENT, JUDY M., PERSON, DONALD A., CLAYBAUGH, JOHN R., WITTLER, ROBERT R., WEISSE, MARTIN E., REGNERY, RUSSELL L., SLATER, LEONARD N.·1998·The Pediatric Infectious Disease Journal

Abstract

OBJECTIVE: To determine the efficacy of azithromycin in the treatment of patients with typical cat-scratch disease. DESIGN: Prospective, randomized, double blind, placebo-controlled clinical trial. SETTING: Large military medical center and its referring clinics. PATIENTS: Active duty military members and their dependents with laboratory-confirmed, clinically typical cat-scratch disease. INTERVENTION: Study participants assigned by randomization to treatment with oral azithromycin or placebo for 5 days. OUTCOME MEASURES: Lymph node volume was calculated using three dimensional ultrasonography at entry and at weekly intervals. The ultrasonographer was blinded to the treatment groups. Endpoint evaluations were predetermined as time in days to 80% resolution of the initial total lymph node volume. RESULTS: Demographic and clinical data showed that the azithromycin and placebo treatment groups were comparable at entry although the placebo group tended to be older. Eighty percent decrease of initial lymph node volume was documented in 7 of 14 azithromycin-treated patients compared with 1 of 15 placebo-treated controls during the first 30 days of observation (P = 0.026). After 30 days there was no significant difference in rate or degree of resolution between the two groups. CONCLUSIONS: Treatment of patients with typical cat-scratch disease with oral azithromycin for five days affords significant clinical benefit as measured by total decrease in lymph node volume within the first month of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00006454-199806000-00002

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 351

Metadata

Authors
BASS, J. W., FREITAS, B. C., FREITAS, A. D., SISLER, C. L., CHAN, D. S., VINCENT, J. M., PERSON, D. A., CLAYBAUGH, J. R., WITTLER, R. R., WEISSE, M. E., REGNERY, R. L., & SLATER, L. N.
Venue
The Pediatric Infectious Disease Journal
Published
1998-06
Volume
17
Issue
6
Pages
447-452
ISSN
0891-3668 (ISSN-L)
OpenAlex
W1965140025
Cited by
351
References
8
FWCI
11.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. https://app.cochat.ai/papers/10.1097/00006454-199806000-00002
The paper
BASS, J. W., FREITAS, B. C., FREITAS, A. D., SISLER, C. L., CHAN, D. S., VINCENT, J. M., PERSON, D. A., CLAYBAUGH, J. R., WITTLER, R. R., WEISSE, M. E., REGNERY, R. L., & SLATER, L. N. (1998). Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. The Pediatric Infectious Disease Journal. https://doi.org/10.1097/00006454-199806000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.